読み込み中
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
前日終値
$3.11
−$0.02 · -0.64%
日中の時刻はETです。市場データは遅延する場合があります。
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
日中レンジ
現在 $3.11
52週レンジ
現在 $3.11
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
45
適正価値
センチメント
51
まちまち
リスク
66
高リスク
モメンタム
19
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
日中レンジ
現在 $3.11
52週レンジ
現在 $3.11
営業利益
純利益
| 指標（USD） | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上原価 | 1.2万 USD | — | — | — | — |
| 粗利益 | −1.2万 USD | — | — | — | — |
| 研究開発 | 714.4万 USD | 472.5万 USD | 222.5万 USD | 74.5万 USD | 4069 USD |
| 販売・一般管理 | 989万 USD | 686.3万 USD | 524.9万 USD | 124.5万 USD | 1359.02万 USD |
| 営業費用 | 1702.2万 USD | 1158.8万 USD | 1203万 USD | 199万 USD | 1359.43万 USD |
| 受取利息 | 31.9万 USD | 35.4万 USD | 12.7万 USD | — | — |
| 支払利息 | — | 17.6万 USD | 7.9万 USD | — | 21.81万 USD |
| 減価償却費と償却費 | 1.2万 USD | 18.3万 USD | 8.1万 USD | — | — |
| 営業利益 | −1703.4万 USD | −1158.8万 USD | −1203万 USD | −199万 USD | −1359.43万 USD |
| 純利益 | −1671.5万 USD | −1141万 USD | −1542.6万 USD | −199万 USD | −1332.87万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
